INS and endometrial carcinoma: This effect is likely due to its activity at the insulin-like growth factor-1 receptor, promoting proliferation and angiogenesis, which can be demonstrated by the positive correlation between diabetes and breast and gynaecological cancers.15 Insulin-mediating effects of metformin, then, show evidence of reducing incidence and improving survival among these malignancies, although the evidence is mixed.16, 17 The link between insulin resistance and cell proliferation offers an intriguing potential therapeutic target to reverse hyperplasia and prevent endometrial carcinoma.